I Want My DNA!

Writing in the New Scientist, Daniel MacArthur and Caroline Wright say that when it comes to DTC genetic testing, they "believe that regulation is needed, but are worried that it will focus too heavily on 'protecting' consumers from their own genomes." The authors note that once "lauded" as Time's invention of the year, personal genome scans have had a hard time "living up to that promise," and consequently their medical value has been limited. But, MacArthur and Wright say, not all DTC companies hold themselves to the same standards.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.